Humanized antibody
A genetically engineered mouse antibody in which the protein sequence has been modified to increase the similarity of the antibody to human antibodies. This is to prevent a mouse-specific antibody response in humans treated with the antibody.
Human epidermal growth factor receptor 2 (HeR2; also known as eRBB2). A type i membrane glycoprotein that is a member of the eRBB family of tyrosine kinase receptors. This tumour-associated antigen is overexpressed in 10-40% of breast cancer and other carcinomas.
Complement-dependent cytotoxicity
(CDC). A mechanism of killing cells in which antibody, bound to the target cell surface, fixes complement, which results in assembly of the membrane attack complex that punches holes in the target cell membrane resulting in subsequent cell lysis.
Immunoreceptor tyrosine-based activation motif (iTAm) . A sequence that is present in the cytoplasmic domains of the invariant chains of various cell-surface immune receptors. Following phosphorylation of their tyrosine residues, iTAms function as docking sites for SRC homology 2 (SH2)-domain-containing tyrosine kinases and adaptor molecules, thereby facilitating intracellular-signalling cascades.
Immunoreceptor tyrosine-based inhibitory motif (iTim) . A motif that is present in the cytoplasmic domain of several inhibitory receptors. After ligand binding, iTims are tyrosine phosphorylated and recruit inhibitory phosphatases.
FcγRs can transduce activating signals through immunoreceptor tyrosine-based activation motifs (ITAMs) or deliver inhibitory signals through immunoreceptor tyrosinebased inhibitory motifs (ITIMs). The main inhibitory FcγR is the single chain FcγRIIB (also known as CD32) whereas most Fc-dependent stimulatory signals are transduced by FcγRI (also known as CD64) and FcγRIIIA (also known as CD16A), both of which require an accessory ITAMcontaining γ-chain to initiate signal transduction 5 . FcγRI is a high-affinity receptor expressed by macrophages, dendritic cells (DCs), neutrophils and eosinophils 5 . FcγRIIIA is the primary activating FcγR expressed by natural killer (NK) cells, DCs, macrophages and mast cells, and is required for NK cell-mediated antibodydependent cell-mediated cytotoxicity (ADCC) 5 . FcγRIIIB (also known as CD16B) is a glycophosphatidylinositol (GPI)-anchored protein that, unlike FcγRIIIA, does not contain the common γ-chain and is exclusively expressed on human neutrophils.
The binding of IgG antibodies to tumour cells enables the recognition of these targets by immune effector populations that express Fcγ receptors, such as NK cells, neutrophils, mononuclear phagocytes and dendritic cells. Cross-linking of FcγRs on these cells promotes ADCC and tumour cell destruction (FiG. 1) . Following tumour cell lysis, antigen-presenting cells can present tumour-derived peptides on MHC class II molecules and promote CD4 + T cell activation. Additionally, in a process known as cross-presentation, tumour-derived peptides can be presented on MHC class I molecules, resulting in activation of CD8 + cytotoxic T cells (see below)
.
FcRn are structurally distinct from FcγRs, and are related to MHC class I molecules. They bind both IgG antibodies and albumin in a pH-dependent manner, with optimal binding occurring at acidic pH. The role of FcRn in the passive transfer of maternal humoral immunity from mother to fetus has been well characterized 6 . FcRn also has an important role in the maintenance of serum IgG and can contribute to the long half-life seen with this isotype (FiG. 1) . FcRn expressed on the vascular endothelium can bind IgG by its Fc domain, returning it to the circulation, or protecting it from transcytotic lysosomal catabolism en route to the lymphatics 6 . FcRn-IgG interactions could be useful therapeutically, and efforts to manipulate the binding of monoclonal IgG to FcRn to enhance the serum half-life of IgG are underway 7 . In addition to regulating the serum half-life of human IgG, FcRn may also contribute to antibody-mediated antigen presentation 8 .
Targeting tumours and their microenvironment
Many of the tumour-expressed targets for therapeutic antibodies are growth factor receptors that show increased expression during tumorigenesis. By blocking ligand binding and/or signalling through these receptors, monoclonal antibodies may serve to normalize growth rates, induce apoptosis and/or help sensitize tumours to chemotherapeutic agents 9 . In addition, antibodies that target the tumour microenvironment and inhibit processes such as angiogenesis have shown therapeutic promise.
Blockade of ligand binding and signalling perturbation.
Members of the EGFR family, including EGFR, HER2, HER3 (also known as ERBB3) and HER4 (also known as ERBB4), are frequently overexpressed in solid tumours and are the target of many currently used therapeutic antibodies. Cetuximab (Erbitux; ImClone Systems/ Bristol-Myers Squibb), a chimeric EGFR-specific IgG1 monoclonal antibody, functions by preventing binding of activating ligand 10 and by preventing receptor dimerization, a crucial step for initiating EGFR-mediated signal transduction 11 . Panitumumab (vectibix; Amgen), a fully humanized IgG2 isotype antibody that is specific for EGFR, works by a similar mechanism as cetuximab 12 but, unlike cetuximab, it does not promote ADCC. Both of these agents have been used as second-or third-line therapy for the treatment of metastatic colorectal cancer 12 . In contrast to the EGFR-specific antibody panitumumab, cetuximab is often used in combination with other chemotherapeutic regimens. Combining cetuximab therapy with folinic acid, 5-fluorouracil and irinotecan (FOlFiRi chemotherapy) has been shown to prolong progression-free survival in patients with metastatic colon cancer, whose tumours harbour wild-type KRAS alleles 13 . By contrast, these therapeutic agents are ineffective when KRAS is mutated 13 . A fully human EGFR-specific antibody, Necitumumab (IMC-11F8; Bristol-Myers Squibb/Eli Lilly/ImClone Systems) was recently described and shown to be well tolerated in patients with advanced solid malignancies 14 .
Timeline | 100 years of progress -from 'magic bullets' to clinical reality 
Cross-presentation
The ability of certain antigenpresenting cells to load peptides that are derived from exogenous antigens onto mHC class i molecules and present these at the cell surface. This property is atypical, as most cells exclusively present peptides derived from endogenous proteins on mHC class i molecules.
angiogenesis
The process of developing new blood vessels. Angiogenesis is important in the normal development of the embryo and fetus. it is also important for tumour growth.
FOLFIRI chemotherapy
A chemotherapy regimen for the treatment of colorectal cancer, made up of the drug folinic acid (leucovorin), fluorouracil (5-FU) and irinotecan (Camptosar).
Heregulin
A family of ligands known to bind the HeR3 and HeR4 receptors, also capable of inducing phosphorylation of HeR2.
In addition to targeting the complete form of EGFR, efforts are underway to target a truncated form of the receptor (EGFRvIII; which has an in-frame deletion of exons II-Iv) that is found in patients with glioblastoma, head and neck cancer and non-small-cell lung carcinoma 15 . A Phase I study using the EGFRvIIItargeting monoclonal antibody 806 (Zymed), which targets EGFR as it dimerizes following ligand binding 16 , showed good antibody penetration of tumour tissue and no significant toxicities in patients with metastatic disease 17 . In contrast to EGFR, HER2 has no known ligand, and antibodies targeting this receptor function mainly to inhibit receptor homo-and hetero-dimerization and internalization, rather than by blocking ligandbinding 18 . HER2 is gene-amplified and overexpressed in approximately 30% of invasive breast cancers and is overexpressed, although rarely gene-amplified, by some adenocarcinomas of the lung, ovary, prostate and gastrointestinal tract 18 . Trastuzumab (Herceptin; Genentech/ Roche), a humanized IgG1 antibody, is used for the treatment of invasive breast cancer that exhibits gene amplification and overexpression of HER2. Trastuzumab monotherapy showed a 35% objective response rate in patients with metastatic breast cancer not previously receiving chemotherapy 19 . The mechanisms of action by which trastuzumab exerts its anti tumour effects include inhibition of receptor dimerization, endocytic destruction of the receptor and immune activation 20 . Another HER2-directed antibody, pertuzumab (Omnitarg; Genentech/Roche), binds at a distinct site from trastuzumab and sterically inhibits receptor dimerization 21 .
Synergistic antitumour effects of combination therapy with pertuzumab and trastuzumab have been reported in pre-clinical models 22 . A new HER3-targeted antibody, MM-121 (Merrimack Pharmaceuticals), is currently being developed and has been shown to specifically bind HER3, inhibit growth of mouse xenograft tumours and block heregulin-dependent signalling through the protein kinase AKT, leading to tumour cell death 23 . Efforts to target HER4 are underway; however, the biological significance of HER4 expression in cancer is poorly understood. HER4 has been reported to be both upregulated and downregulated in cancer, presumably owing to the presence of many isoforms and its prognostic value is yet to be determined 24 . Treatment with a monoclonal antibody targeting selected HER4 isoforms resulted in decreased proliferation of two tumour cell lines; mechanistically, this was due to inhibition of HER4 phosphorylation and cleavage and the downregulation of HER4 expression 24 .
Targeting the tumour microenvironment. Strategies to target crucial events in the tumour microenvironment have shown therapeutic benefit in preclinical and clinical settings. For example, many solid tumours express vascular endothelial growth factors (vEGFs), which binds to its receptor on the vascular endothelium to stimulate angiogenesis. Bevacizumab (Avastin; Genentech), a vEGFA-specific humanized monoclonal antibody, blocks binding of vEGF to its receptor and is approved for the treatment of breast, colorectal and non-small-cell lung cancer in combination with cytotoxic chemotherapy 25 . Efforts to target vEGF receptors (vEGFRs) by other EGFR, epidermal growth factor receptor; HER2, human epidermal growth factor receptor 2; VEGF, vascular endothelial growth factor.
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Cell membrane molecules are also underway. Ramucirumab (IMC-1121B, ImClone Systems), a fully human monoclonal antibody against vEGFR2, has been shown to inhibit growth of xenografts in mice 26 . A multi-centre Phase III clinical trial investigating the effect of combination therapy with ramucirumab and the chemotherapy agent docetaxel in women with HER2-negative metastatic breast cancer is currently underway 27 . Similarly, efforts to target vEGFR1 with the fully human antibody IMC-18F1 are currently underway and have shown preclinical promise 28 . The increasing therapeutic use of bevacizumab has led to an increase in bevacizumab-resistant tumours owing to upregulation of other pro-angiogenic mediators, such as platelet-derived growth factor (PDGF). PDGF-receptor (PDGFR)-signalling is important in maintaining the endothelial support system, which stabilizes and promotes the growth of new blood vessels 29 . Blockade of PDGFR signalling by a PDGFRβ-specific human antibody has been shown to synergize with anti-vEGFR2 therapy in preclinical models and suggests the utility of anti-PDGFRβ therapy in the setting of bevacizumab resistance 30 .
Targeting immune cells.
In addition to directly targeting tumour cells, numerous antibody-based therapeutic strategies have been developed to target cells of the immune system with the goal of enhancing antitumour immune responses. Here, we consider the targeting of immunoregulatory co-receptors, antibodybased strategies aimed at reversing tumour-mediated immunosuppression and Fc domain modulation to alter the specificity of Fc receptor-targeting and activation.
CD40 is a member of the tumour necrosis factor receptor (TNFR) family and is expressed by B cells, DCs, monocytes and macrophages. Engagement of CD40 on antigen-presenting cells leads to the upregulation of costimulatory molecules, production of pro-inflammatory cytokines and facilitation of cross-presentation of antigens 31 . Many tumours have been shown to express CD40, including carcinomas of the ovary, nasopharynx, bladder, cervix, breast and prostate, and the engagement of CD40 can lead to a direct antitumour effect in some tumours in vivo 32 . In one study, the effect of a fully human CD40-specific agonist monoclonal IgG2 (CP-870893; Pfizer) 
Regulatory T (T Reg ) cell
A type of CD4 + T cell that is characterized by its expression of forkhead box P3 (FOXP3) and high levels of CD25. T Reg cells can suppress many types of immune responses.
was assessed in 29 patients with advanced solid tumours. The results showed four partial responses (all patients with melanoma) and one complete resolution 33 . Another CD40-specific antibody, dacetuzumab (SGN-40; Seattle Genetics), is a humanized IgG1 that can induce tumour cell apoptosis as well as ADCC, and was recently shown to exert its antitumour effects by inducing Fc-mediated phagocytosis of tumour cells by macrophages 34 . Early clinical trials suggest that dacetuzumab also has promise in the treatment of patients with non-Hodgkin's lymphoma 35 . Cytotoxic T lymphocyte antigen 4 (CTLA4), a homologue of CD28, is a negative regulator of T cell activation that binds CD80 (also known as B7.1) and CD86 (also known as B7.2) with higher affinity than CD28. CTLA4 blockade enhanced rejection of CD86-negative tumours, implying that this was not through direct effects on the tumour, and reduced the growth of established tumours 36 . Furthermore, CTLA4 blockade resulted in protection from secondary tumour challenge, suggesting that immunological memory developed 36 . Subsequent studies showed that treatment with a CTLA4-specific antibody can prevent and reverse antigen-specific CD8 + T cell tolerance in a CD4 + T cell-dependent manner 37 . Recent work has revealed that enhancement of T cell effector functions, combined with the inhibition of regulatory T (T Reg ) cells, might be responsible for the antitumour effects of CTLA4 blockade 38 . These preclinical data show that CTLA4-specific treatment can enhance adaptive immunity and promote tumour regression.
Two CTLA4-specific monoclonal antibodies have been studied in clinical trials. Tremelimumab (CP-675,206; Pfizer) (IgG2 isotype) and ipilimumab (MDX-010; Bristol-Myers Squibb/Medarex) (IgG1 isotype) can induce delayed disease regression in patients with metastatic melanoma 39 . Although this antibody is no longer being evaluated for this indication, these results demonstrate the potential value of this approach. In addition, ipilimumab is being investigated as a treatment option for men with hormone-refractory prostate cancer 40 . On a cautionary note, dose-dependent immune-related toxicity has been reported with CTLA4-specific antibodies; side-effects include rash, vitiligo, diarrhoea, colitis, nephritis with azotemia, hypophysitis and hepatitis 41 . Antibodies targeting OX40, PD1 and CD137 have also shown pre-clinical promise (TABle 2) but have not yet undergone extensive clinical testing.
Targeting immunosuppressive tumour microenvironments. Tumour cells and the surrounding stroma can produce strongly immunosuppressive cytokines and growth factors. Among the best characterized of these factors is transforming growth factor-β (TGFβ), which can inhibit T cell activation, differentiation, and proliferation 42 . TGFβ has been shown to promote tumour escape from the immune system, and high plasma levels of TGFβ correlate with a poor outcome in various malignancies 42 . GC1008 is a fully human TGFβ-specific antibody that binds to all three isoforms of TGFβ 43 . Recruitment is currently underway to a clinical trial of GC1008 in patients with metastatic kidney cancer or malignant melanoma (clinicaltrials.gov.NCT00899444).
The production of immunosuppressive factors such as TGFβ can result in the accumulation of suppressive CD4
+ T Reg cells 44 , which is associated with poor clinical outcomes 45 . Treatment with CD25-specific monoclonal antibodies to deplete T Reg cells has shown remarkable potential in pre-clinical models of various malignancies 46 and has been shown to suppress tumour formation and metastasis in a mouse model of breast cancer 47 . Clinically, the humanized IgG1 CD25-specific monoclonal antibody daclizumab (Zenapax; Roche) is well tolerated, resulted in depletion of T Reg cells in patients with metastatic breast cancer and may synergize with peptide vaccines targeting human telomerase reverse transcriptase and the anti-apoptotic protein survivin 48 . However, CD25-specific therapy could potentially deplete effector T cells that have upregulated CD25 following activation. In addition, further studies are required to understand the role of CD25-negative T Reg cells in the setting of cancer 48 .
Fc domain modulation.
As discussed below, numerous pre-clinical studies suggest that ADCC is an important mechanism of action for several monoclonal antibodies used in cancer immunotherapy. Efforts to modify the Fc domain primary structure using computational and high-throughput screening have resulted in Fc domains with higher affinity for FcγRIIIA and an enhancement of ADCC 49 . The new CD20-specific antibodies ocrelizumab (2H7; Genentech/Roche/Biogen Idec) and AME-133 (Applied Molecular Evolution/Eli Lilly) both contain mutated Fc domains and promote enhanced ADCC compared with rituxumab (Rituxan/Mabthera; Genentech/ Roche/Biogen Idec) 50 . Modification of Fc domain oligosaccharide content provides another mechanism for enhancing ADCC. Most of the currently used therapeutic antibodies are highly fucosylated owing to the nature of the cell lines used for manufacturing. However, antibodies with defucosylated oligosaccharides show a significant enhancement in ADCC in vitro and enhanced in vivo antitumour activity 50 . Phase I trials of non-fucosylated antibodies specific for CC-chemokine receptor 4 (CCR4), which is expressed by some lymphoid neoplasms and is used by T Reg cells to facilitate their migration to the tumour microenvironment 45 , have shown promise and early data suggest efficacy at significantly lower doses than conventional therapeutic antibodies 50 .
How do cancer-specific antibodies work?
Many mechanisms have been proposed to explain the clinical antitumour activity of unconjugated tumour antigenspecific monoclonal antibodies. As discussed above, the ability of some antibodies to disrupt signalling pathways involved in the maintenance of the malignant phenotype has received widespread attention. However, the ability of antibodies to initiate tumour-specific immune responses has been less well recognized. Here, we describe these mechanisms and discuss the potential for using antibodies to manipulate the host immune response to tumours. we focus on three mechanisms: ADCC, CDC and the induction of adaptive immune responses.
Antibody-dependent cellular cytotoxicity. Several studies have established the importance of Fc-FcγR interactions for the in vivo antitumour effects of certain monoclonal antibodies in murine models and clinical trials. A seminal paper showed that the antitumour activities of trastuzumab and rituximab (Rituxan/Mabthera; Genentech/ Roche/Biogen Idec) were lower in FcγR-deficient mice than wild-type mice 51 . The role of FcγR in the antitumour response has been further supported by the finding that polymorphisms in the gene encoding FcγRIII, which lead to higher binding of antibody to FcγRIII, are associated with high response rates to rituximab in patients with follicular non-Hodgkin's lymphoma 52 . A separate study that compared clinical responses to rituximab in patients with follicular lymphoma suggested that both FcγRIII and FcγRIIB had a role in the response to rituximab 53 . More recent findings show that polymorphisms in genes encoding FcγRs are associated with clinical responses to other antibodies, including trastuzumab 54 and cetuximab 55 . Patients with breast cancer who responded to trastuzumab with complete or partial remission have been found to have a higher capability to mediate in vitro ADCC in response to trastuzumab than patients whose tumours failed to respond to therapy 54 . ADCC enhancement through Fc domain modification has shown promise in the development of next generation antibodies. For example, a CD19-specific antibody with increased FcγRIIIA binding affinity mediated significantly increased ADCC compared to its parental antibody and rituximab 56 . The in vivo infusion of this high affinity antibody efficiently cleared malignant B cells in cynomolgus macaques (Macaca fascicularis) 57 .
Complement-dependent cytotoxicity. Most clinically approved monoclonal antibodies that mediate ADCC also activate the complement system. However, alemtuzumab (Campath/MabCampath; Genzyme/Bayer), which recognizes CD52 expressed on mature B and T cells, activates human complement and has antitumour activity in patients with chronic lymphocytic leukaemia, but it does not mediate ADCC 58 . The relationship between complement activation and therapeutic activity is also suggested from studies with several clinically approved monoclonal antibodies. The CD20-specific monoclonal antibody rituximab has been found to be dependent, in part, on CDC for its in vivo efficacy. In a preclinical therapy model, antitumour protection by rituximab was completely abolished in C1q-deficient mice 59 . It was also shown that depletion of complement decreased the therapeutic activity of rituximab in a xenograft model of human B cell lymphoma 60 . The importance of rituximabmediated CDC is supported by the demonstration that genetic polymorphisms in the C1QA gene correlate with clinical response to rituximab therapy in patients with follicular lymphoma 61 . Optimization of antibody-based complement activities can enhance antitumour activity. For example, the CD20-specific antibody ofatumumab (Arzerra; Genmab/GlaxoSmithKline), which mediates improved CDC, was approved for the treatment of patients with chronic lymphocytic leukaemia (CLL) in 2009. This fully human antibody binds a different epitope than rituximab with improved binding kinetics, and it induces potent tumour cell lysis through improved activation of the classical complement pathway 62 . An initial study in patients with refractory CLL showed a 50% response rate to ofatumumab, suggesting a higher efficacy than rituximab in patients with CLL, although this higher response rate may not be solely due to enhanced CDC 62 . Several studies indicate that both CDC and ADCC can contribute to monoclonal antibody-induced tumour cell lysis. However, the relative clinical importance of each mechanism, and whether these mechanisms are synergistic, additive or antagonistic, remains uncertain. For example, in a mouse model of lymphoma, depletion of complement enhances NK cell activation and ADCC, thus improving the efficacy of the antibody 63 .
Induction of T cell immunity through cross-presentation.
Early research on the antitumour effects of therapeutic antibodies focused on the potential value of passive immunotherapy provided through ADCC and CDC. Interestingly, studies have suggested that the maximal clinical benefit of rituximab is not apparent until months after initiation of therapy, suggesting a role for the adaptive immune system in mediating the long-term benefit of monoclonal antibodies 64 . There is increasing evidence to suggest a role for cross-presentation in the induction of adaptive immune responses following antibody therapy. DCs are capable of presenting peptides from engulfed apoptotic cells on MHC class I molecules to elicit antigen-specific CD8 + T cell responses 65 . In one study, DCs loaded with killed allogeneic melanoma cells induced cytotoxic T lymphocytes (CTLs) that were specific for various melanoma antigens and killed melanoma cell lines in vitro 66 . Another group reported a similar finding using a head and neck squamous cell carcinoma cell line 67 . Induction of adaptive immunity was linked to antibody therapy in a study showing that tumours coated with antibodies could enhance cross-presentation of tumour antigens in a FcγR-dependent fashion 68 , and blockade of the inhibitory receptor FcγRIIB was shown to enhance cross-presentation by DCs 69 . ADCC mediated by monoclonal antibodies might trigger cross-presentation by DCs and promote adaptive immune responses, as DCs can engulf the resultant apoptotic tumour cells and subsequently present tumour antigens on MHC class I and II molecules (FiG. 2) . This dual presentation leads to direct tumour cytotoxicity by CTLs and the generation of CD4 + T cells, which can prime B cells for the production of tumour-specific host antibodies. In addition, cross-presentation can be mediated by the phagocytosis of dying antibody-coated tumour cells through FcγRs 68 .
It is important to note that DC presentation of engulfed tumour antigens can lead to either immunity or tolerance based on the exact nature of the tumour microenvironment 42 . Accordingly, strategies aimed at targeting tolerizing factors in the microenvironment may synergize with tumour-directed antibody therapy by enhancing cross-presentation and breaking local tolerance.
Combination approaches
The antitumour efficacy of many therapeutic antibodies can be enhanced by their use in combination with other immunomodulatory approaches such as chemotherapy, radiotherapy, targeted therapy agents, vaccines or other immunomodulators.
Combinations with cytotoxic chemotherapy. Although chemotherapy has been traditionally thought to be immuno suppressive, recent evidence has challenged this view 70 . Bevacizumab in combination with FOLFIRI chemotherapy resulted in a 10.6 month median duration of progression free survival compared with 6.2 months with FOLFIRI chemotherapy alone 71 . Similarly, trastuzumab in combination with chemotherapy showed a 50% objective response rate compared with 35% with chemotherapy alone in patients with metastatic breast cancer 72 . One small study found that combined treatment with trastuzumab and paclitaxel induced humoral and cellular HER2-specific immune responses that were associated with favourable clinical outcomes in patients with advanced breast cancer 73 . The induction of HER2-specific CD4 + T cells and humoral immune responses indicated that an adaptive immune response against HER2 was induced by this treatment. Similar benefits are also well documented with rituximab, in which inclusion of rituximab in a standard chemotherapy regimen resulted in an overall response rate of 76% compared with 63% with chemotherapy alone in patients with diffuse large B cell lymphoma 74 . The benefit of adding rituximab to chemotherapeutic regimens was also reported in follicular and mantle cell lymphoma 75 .
Combinations with radiation. Although radiation therapy has long been viewed as being immunosuppressive, it has been hypothesized that radiation can result in enhanced antitumour immunity 76 . Based on this understanding, investigators have begun to combine radiation and Nature Reviews | Immunology . The safety and efficacy of combining bevacizumab, which targets vEGF, with chemoradiotherapy in advanced rectal cancer was evaluated in a Phase I/II clinical study, and it seemed to be safe and potentially effective 78 . The concentrations of vEGF and pro-inflammatory cytokines, such as interleukin-6 (IL-6) in the blood of these patients significantly correlated with clinical outcomes. However, these studies have not tested the possibility that combinations of radiation with antibody therapy can induce host-protective adaptive immune responses. In a Phase II clinical study, which reported the use of a recombinant cancer vaccine combined with standard definitive radiotherapy in patients with localized prostate cancer, it was shown that combination treatment can generate the development of T cells directed against other tumour-associated antigens not present in the vaccine 79 . Recent evidence suggests that radiation therapy might activate innate immune effector cells through Toll-like receptor-dependent mechanisms, thereby augmenting the adaptive immune response to cancer 81 . The effects of granulocyte colony-stimulating factor (G-CSF)-mediated neutrophil stimulation on rituximab activity have been studied in a Phase I/II trial in patients with low-grade lymphoma 83 . Although the overall response rate was similar to that reported for rituximab monotherapy, remission duration in this pilot Phase II study was remarkably long. A recent Phase I study showed the feasibility of integrating IL-2 into a regimen of ch14.18 (an antibody targeting ganglioside GD2, a cell surface antigen highly expressed on human neuroblastomas) plus granulocytemacrophage colony-stimulating factor (GM-CSF) in an effort to boost effector immune responses 84 .
Combining targeted therapy agents. Combination therapy using monoclonal antibodies and small-molecule tyrosine kinase inhibitors, which function to block activation of intracellular signalling in tumour cells or stromal cells following receptor engagement, has been proposed as an approach to enhance clinical efficacy through more effective cancer-specific signalling perturbations with concurrent activation of immune effector mechanisms. The effect of combining SU6668 (Sugen Pharmaceuticals) (a vEGFR2, PDGFRβ and FGFR1 tyrosine kinase inhibitor) with a mouse CD86-IgG fusion protein, which provides a stimulatory signal to CD86, was tested in pre-clinical mouse models. These studies showed enhanced anti tumour and anti-metastatic responses, as well as an increase in tumour-infiltrating CD8 + T cells, compared with monotherapy 85 . Similarly, when the effect of combining cetuximab with gefitinib (Iressa; AstraZeneca) -an EGFR tyrosine kinase inhibitor -was investigated in preclinical models, combination treatment resulted in permanent regression of large tumours at suboptimal doses, whereas cetuximab monotherapy induced transient regression 
Co-stimulation
Receptor-mediated signals required in addition to antigen-receptor engagement to achieve complete lymphocyte activation.
only at the highest doses 86 . Combination therapy provided superior inhibition of EGFR-signalling, greater inhibition of cell proliferation and vascularization, and enhanced apoptosis 86 . A Phase I clinical trial showed the feasibility of gefitinib and cetuximab combination therapy in patients with refractory non-small-cell lung cancer 87 . Recent work has shown enhanced efficacy of combination therapy using lapatinib (Tykerb; GlaxoSmithKline), a small molecule HER2-specific tyrosine kinase inhibitor, and trastuzumab compared with monotherapy 88 . In addition to its tyrosine kinase inhibitor activity, lapatinib promoted the formation of inactive HER2 homodimers at the plasma membrane, resulting in enhanced trastuzumab-mediated ADCC 88 . A recent Phase III clinical trial showed that trastuzumab and lapatinib combination therapy improved progression-free survival compared with lapatinib monotherapy in patients with HER2-positive, trastuzumab-refractory metastatic breast cancer 89 .
Combinations with vaccines.
Given the evidence suggesting that monoclonal antibody therapy can have both direct and indirect effects on the adaptive immune response, combining antibody therapy with vaccination strategies might prove to be efficacious. Using irradiated GM-CSF-producing B16 melanoma cells as a vaccination strategy, it was shown that the addition of CTLA4-specific antibody was more effective at eradicating established B16 tumours than vaccination alone 90 . The enhanced antitumour effect depended on CD8 + T cells and NK1.1 + cells 90 . Similarly, in a mouse tumour model induced by the subcutaneous injection of a colon carcinoma, the addition of the TGFβ-specific antibody ID11 to an irradiated tumour cell vaccine significantly enhanced antitumour activity in a CD8 + T cell-dependent manner 91 . Addition of TGFβ-specific antibody to a peptide vaccine was found to increase the number and lytic activity of tumour antigen-specific CTLs, but it had no effect on the numbers of T Reg or T H 17 cells 92 . Therefore, pre-clinical data support the hypothesis of combining antibodies that target the immunosuppressive tumour microenvironment with vaccination. Similarly, studies combining antibodies specific for tumour antigens, such as trastuzumab, with peptide-based vaccines that stimulate HER2-specific T cell responses are underway and have shown initial clinical promise 93 .
Other Structures
Advances in antibody engineering have generated novel antibody constructs that allow the testing of new antibody-based therapy strategies. Bispecific antibodies, which simultaneously target epitopes on tumour cells as well as molecules expressed by immune effector cells, have been known for some time to have equivalent or superior potency compared with their monospecific IgG counterparts 119 . However, they showed limited clinical efficacy: this was largely attributed to their short half-lives and the host toxicity caused by concurrent T cell co-stimulation. Bispecific T cell engager (BiTE) molecules, which use a new format of bispecific antibody that targets both CD3 and another antigenic marker, are formed by linking two Fv fragments using flexible linkers. BiTE molecules show enhanced tumour cell lysis, high protein stability and efficacy at low T cell/target cell ratios 94 . MT110 (Micromet/ MedImmune), a BiTE molecule specific for human epithelial cell adhesion molecule (EPCAM) and CD3, has shown antitumour efficacy in a xenograft model 95 and is currently being studied in a Phase I clinical trial (clinicaltrials.gov, NCT00635596).
Additional advances in protein engineering have focused on equipping non-immunoglobulin family proteins with novel binding sites and are collectively called engineered protein scaffolds. In contrast to antibodies, scaffolds usually consist of monomeric proteins or of the extramembrane domain of a surface receptor that is highly stable and compatible with high yield expression systems 96 . Examples of engineered protein scaffolds include designed ankyrin repeat domains (DARPins) and adnectins, which are composed of the 10 th extracellular domain of fibronectin III that folds to adopt an immunoglobulin-like structure. A vEGFR2-specific adnectin was recently reported to possess antitumour activity against human tumour xenografts 97 .
Future Prospects
FcγRs provide the key link between therapeutic antibodies and the cellular immune system, and they enable monoclonal antibodies to induce adaptive immune responses. The magnitude and quality of the innate immune responses induced by ADCC is likely to influence the ensuing adaptive immune response. ADCC-inducing approaches therefore offer a promising basis to improve antibody efficacy. New insights from animal models and clinical trials suggest a rationale for ADCC-based combination therapy, approaches that promote antigen presentation (for example, Toll-like receptor agonists 98 ), co-stimulation (for example, with CTLA4-specific antibody) and T cell activation or expansion (for example, using IL-2 (ReF. 81) ). Furthermore, antibody structures can be modified to selectively engage activating rather than inhibitory FcγRs. Fusion antibodies with immunostimulatory motifs that induce and amplify antigen presentation and co-stimulation have also shown promise 99 . However, new methods and more investigation are still needed to more accurately detect and monitor immune responses directed against tumour antigens in vivo.
Conclusion
The past century has witnessed the evolution of the 'magic bullet' from concept to clinical reality. The attributes of target specificity, low toxicity and the ability to activate the immune system suggest the continuing promise of therapeutic antibodies. Therapeutic antibodies currently provide clinical benefit to patients with cancer and have been established as 'standard of care' agents for several highly prevalent human cancers. The next generation of unconjugated antibody therapies will undoubtedly yield many effective new treatments for cancer over the next decade. These advances will arise from the identification and validation of new targets, the manipulation of tumour-host microenvironment interactions, and the optimization of antibody structure to promote the amplification of antitumour immune responses.
